A randomised, double blind, placebo controlled study of celecoxib, a selective cyclooxygenase 2 inhibitor, on duodenal polyposis familial adenomatous polyposis

Gut

Volumn 50, Issue 6, 2002, Pages 857-860

  Phillips, R K S ^a   Wallace, M H ^a   Lynch, P M ^b   Hawk, E ^b   Gordon, G B ^c   Saunders, B P ^d   Wakabayashi, N ^b   Shen, Y ^b   Zimmerman, S ^b   Godio, L ^c   Rodrigues Bigas, M ^b   Su, L K ^b   Sherman, J ^c   Kelloff, G ^e   Levin, B ^b   Steinbach, G ^b   Abbruzzese, J ^f   Dubois Jr , R ^c   Fujimura, T ⁱ   Hittleman, W ⁱ   Jester, S ^g   King, K ^g   Patterson, S ^h   Schumacher, M ^f   more..

^a IMPERIAL CANCER RESEARCH FUND   (United Kingdom)

^b ST MARK S HOSPITAL   (United Kingdom)

^c UNIVERSITY OF TEXAS   (United States)

^d Chemoprevention   (United States)

^e ROSWELL PARK CANCER INSTITUTE   (United States)

^f NATIONAL CANCER INSTITUTE   (United States)

^g VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^h PFIZER INC   (United States)

ⁱ National Cancer Institute ^*

Author keywords

[No Author keywords available]

Indexed keywords

CELECOXIB; CYCLOOXYGENASE 2 INHIBITOR; PLACEBO;

ADENOMATOUS POLYP; ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; COLON CARCINOGENESIS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE ASSOCIATION; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; ENDOSCOPY; FEMALE; HUMAN; MALE; POLYPOSIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME; TREATMENT PLANNING;

ADENOMATOUS POLYPOSIS COLI; ADULT; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTINEOPLASTIC AGENTS; CYCLOOXYGENASE INHIBITORS; DOUBLE-BLIND METHOD; DUODENAL NEOPLASMS; FEMALE; HUMANS; INTESTINAL POLYPS; MALE; PYRAZOLES; SULFONAMIDES; TREATMENT OUTCOME;

EID: 0036114348     PISSN: 00175749     EISSN: None     Source Type: Journal    
DOI: 10.1136/gut.50.6.857     Document Type: Article

References (22)

1. Evidence for adenoma-carcinoma sequence in the duodenum of patients with familial adenomatous polyposis
2. Over expression of p53 in duodenal tumours in patients with familial adenomatous polyposis
3. Surgical polypectomy of duodenal adenomas in familial adenomatous polyposis: An experience of two European centres
4. Surgical treatment of severe duodenal polyposis in familial adenomatous polyposis
5. Upper gastrointestinal cancer in patients with familial adenomatous polyposis
6. Randomized controlled trial of the effect of sulindac on duodenal and rectal polyposis and cell proliferation in patients with familial adenomatous polyposis
7. Effect of sulindac on small polyps in familial adenomatous polyposis
8. Prospective randomized study of sulindac versus calcium and calciferol for upper gastrointestinal polypsis in familial adenomatous polyposis
9. Gastrointestinal toxicity of nonsteroidal antiinflammatory drugs
10. Mechanism of action of anti-inflammatory drugs
11. Update on clinical development with celecoxib, a new specific COX-2 inhibitor: What can we expect?
12. Outcome of specific COX-2 inhibition in rheumatoid arthritis
13. Preliminary study of the safety and efficacy of SC-58635, a novel cyclooxygenase 2 inhibitor - Efficacy and safety in two placebo-controlled trials in osteoarthritis and rheumatoid arthritis, and studies of gastrointestinal and platelet effects
14. Suppression of intestinal polyposis in APC 716 knockout mice by inhibition of cyclooxygenase 2 (COX-2)
15. Aspirin use and chronic diseases: A cohort study of the elderly
16. Aspirin use and reduced risk of fatal colon cancer
17. Treatment of colonic and rectal adenomas with sulindac in familial adenomatous polyposis
18. Early expression of cyclooxygenase-2 during sporadic colorectal carcinogenesis
19. Up-regulation of cyclooxygenase 2 gene expression in human colorectal adenomas and adenocarcinomas
20. Chemopreventive activity of celecoxib, a specific cyclooxygenase-2 inhibitor, against colon carcinogenesis
21. The effect of celecoxib, a cyclooxygenase inhibitor, on familial adenomatous polyposis